drugset

drugset / Trial / NCT00147901

Fludarabine, Cyclophosphamide, and Alemtuzumab in Patients With B-cell Chronic Lymphatic Leukemia (B-CLL)

NCT00147901 ↗

Phase 2 Completed 61 enrolled German CLL Study Group MedacSchering Onkologie · collab University of Cologne · collab

NaSingle-groupOpen-labelTreatment

Summary

This study aims to assess the short term efficacy of a combination immunochemotherapy in patients with relapsed B-cell chronic lymphatic leukemia.

Timeline

Start: 2005-01
Primary completion: 2008-11
Completion: 2011-11

Publications

Results Elter T, James R, Busch R, Winkler D, Ritgen M, Bottcher S, Kahl C, Gassmann W, Stauch M, Hasan I, Staib P, Fischer K, Fink AM, Bahlo J, Buhler A, Dohner H, Wendtner CM, Stilgenbauer S, Engert A, Hallek M. Fludarabine and cyclophosphamide in combination with alemtuzumab in patients with primary high-risk, relapsed or refractory chronic lymphocytic leukemia. Leukemia. 2012 Dec;26(12):2549-52. doi: 10.1038/leu.2012.129. Epub 2012 May 15. No abstract available.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Alemtuzumab	Monoclonal antibody	30 mg	Subcutaneous
Subject	Cyclophosphamide	Other / unclassified	200 mg/m2	Intravenous
Subject	Fludarabine	Small molecule	25 mg/m2	Intravenous

Indications